August 14, 2017 (Shareholders Foundation) - An investigation on behalf of investors of Dr.Reddys Laboratories Ltd (ADR) (NYSE:RDY) shares over potential securities laws violations by Dr.Reddys Laboratories Ltd and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Dr.Reddys Laboratories Ltd (ADR) (NYSE:RDY) concerning whether a series of statements by Dr.Reddys Laboratories Ltd regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

India based Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines.

Shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) reached as high as $67.26 per share in August 2015.

On November 6, 2015, Dr.Reddy's Laboratories Ltds announced that it had received a warning letter issued by the U.S. Food and Drug Administration (FDA) concerning inadequate quality control standards at three of the Company's manufacturing plants in India.

On August 10, 2017, Dr.Reddy's Laboratories Ltds disclosed that the Regulatory of Germany (Regierung von Oberbayern) did not renew the good manufacturing practices (GMP) compliance certificate of a formulations manufacturing unit of the Company's German subsidiary Betapharm Arzneimittel, located in Hyderabad, India, following a recent inspection of the plant. Shares of Dr.Reddy's Laboratories Ltd (ADR) (NYSE:RDY) declined to as low as $30.22 per share on August 10, 2017.